Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular
 Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with
 sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate
 the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC
 under daily-life treatment conditions.
Inclusion Criteria:

 -  Patients with histologically/cytologically confirmed HCC or radiographically diagnosed
 as per AASLD criteria, who are candidates for systemic therapy and for whom a decision
 to treat with sorafenib has been made

 -  Patients must have signed the informed consent form

 -  Patients must have a life expectancy of at least 8 weeks Inclusion criteria must
 follow the approved local product information.

 Exclusion Criteria:

 -  Prior treatment with sorafenib

 -  Concomitant participation in other clinical studies Exclusion criteria must follow the
 approved local product information.